← 返回

2022 年初临床肿瘤学研究亮点

英文原题:Research highlights of clinical oncology early 2022.

查看英文原题

Research highlights of clinical oncology early 2022.

PubMed 2022/07/05(内容时间) Holist Integr Oncol

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

临床肿瘤学的进展高度依赖于癌症研究和临床试验的发展。关于治疗癌症的新治疗药物、制剂或技术,已有大量证据。我们进行了广泛的文献检索,以获取癌症治疗的最新进展。本文简要综述了新发布的临床试验结果,包括手术方式、免疫检查点阻断、CAR-T 细胞疗法、抗体药物偶联物和肿瘤疫苗等。同时讨论了癌症治疗的生物标志物或患者评估。

展开英文摘要原文

Advance in clinical oncology is highly relied on development of cancer research and clinical trials. There has been ample evidence regarding the new therapeutic drugs, agents or techniques for the treatment of cancer.

We did a broad literature search to catch the latest progress in the cancer therapy.

Here is a brief review of the newly released results of clinical trials including surgical modalities, immune checkpoint blockade, chimeric antigen receptor T-cell (CAR T) therapy, antibody-drug conjugates and tumor vaccines, etc. Biomarkers or patient assessment of cancer therapy were also discussed.

论文信息

作者
Wu K
单位
Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.China
文献类型
综述
期刊
Holistic integrative oncology.2022
原文标识
PubMed 37520335 · DOI 10.1007/s44178-022-00006-9